Recently, the latest version of the national medical insurance catalogue was released, and the "strong drug" trastuzumab "subcutaneous preparation" version for breast cancer treatment was included in the new medical insurance catalogue, leading the new trend of breast cancer treatment. In order to further promote the high-quality development of breast cancer prevention and treatment, and let the whole society pay attention to women's health and cancer prevention, recently, the activity of "Joining hands to enter the era of chronic disease management of breast cancer" of Health Science Popularization in Guangdong was successfully held. This activity was carried out in the form of "online+offline". On the one hand, many medical experts popularized breast cancer science through the network platform, and on the other hand, the event sponsor and media reporters went to the front lines of major hospitals in Guangdong Province to carry out in-depth dialogues on breast cancer prevention and treatment, the efficacy of "subcutaneous preparations", and health care under the new medical insurance catalog. Medical experts from Guangzhou, Yangjiang, Zhongshan, Heyuan, Shantou, Chaozhou, Jieyang and other places participated in this science popularization activity, including well-known breast health experts in Guangdong Province. （1） Entry into the new medical insurance directory - "strong drugs" for breast cancer prevention and control enhance the prevention and control effect On December 13, 2023, the National Health Insurance Bureau announced the adjustment results of the national medical insurance directory in 2023, and a total of 126 drugs were added to the national medical insurance drug directory, including 21 tumor drugs. In particular, the "subcutaneous preparation" version of trastuzumab for breast cancer treatment was included in the list of new medical insurance, and was officially implemented on January 1, 2024. It is reported that trastuzumab is a HER2 targeted drug originally developed by Roche for the treatment of breast cancer, which was launched 20 years ago. Among breast cancer patients, HER2 positive breast cancer patients account for about 25%. This subtype has a high degree of malignancy and a poor prognosis. At present, the "Toto double target regimen" of trastuzumab combined with patouzumab has become the standard regimen for the treatment of HER2 positive breast cancer. It has an unshakable position in the anti HER2 treatment, and is known as the "strong drug" in the treatment of breast cancer. The "subcutaneous preparation" version of trastuzumab has entered the new medical insurance directory this time. Since its release in 2013, the subcutaneous formulation of trastuzumab has been a fixed dose ready to use subcutaneous injection of trastuzumab and rHuPH20, which improves tissue permeability, breaks through the limitation of subcutaneous administration of 2ml, and expands subcutaneous administration capacity. In October 2022, the National Drug Administration of China (NMPA) approved the launch of trastuzumab injection (subcutaneous injection) dosage form, which changed the traditional mode of breast cancer treatment and opened a new era of subcutaneous diagnosis and treatment of breast cancer. Multiple clinical studies both domestically and internationally have confirmed the efficacy and safety of trastuzumab as a subcutaneous preparation, resulting in a more relaxed treatment process. First, "subcutaneous preparation" reduces the treatment time of breast cancer patients. In the past, targeted therapy required a infusion time of 30-90 minutes, followed by an hour of observation. If the preparation time is included, the entire treatment process will take 3.5 hours. In contrast, the subcutaneous administration method for tumors is faster, more convenient, and simpler. Patients can complete infusion within 2-5 minutes and receive treatment through a minimally invasive approach,